- Home
- ASMB vs LPTX Comparison
ASMB vs LPTX Comparison
Compare ASMB & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASMB
- LPTX
- Stock Information
- Founded
- ASMB 2005
- LPTX 2011
- Country
- ASMB United States
- LPTX United States
- Employees
- ASMB N/A
- LPTX 52
- Industry
- ASMB Biotechnology: Pharmaceutical Preparations
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ASMB Health Care
- LPTX Health Care
- Exchange
- ASMB Nasdaq
- LPTX Nasdaq
- Market Cap
- ASMB 141.8M
- LPTX 13.2M
- IPO Year
- ASMB 2010
- LPTX N/A
- Fundamental
- Price
- ASMB $18.51
- LPTX $0.34
- Analyst Decision
- ASMB Strong Buy
- LPTX Hold
- Analyst Count
- ASMB 3
- LPTX 1
- Target Price
- ASMB $33.00
- LPTX N/A
- AVG Volume (30 Days)
- ASMB 43.3K
- LPTX 3.3M
- Earning Date
- ASMB 08-07-2025
- LPTX 08-11-2025
- Dividend Yield
- ASMB N/A
- LPTX N/A
- EPS Growth
- ASMB N/A
- LPTX N/A
- EPS
- ASMB N/A
- LPTX N/A
- Revenue
- ASMB $32,154,000.00
- LPTX N/A
- Revenue This Year
- ASMB $0.04
- LPTX N/A
- Revenue Next Year
- ASMB N/A
- LPTX N/A
- P/E Ratio
- ASMB N/A
- LPTX N/A
- Revenue Growth
- ASMB 148.33
- LPTX N/A
- 52 Week Low
- ASMB $7.75
- LPTX $0.22
- 52 Week High
- ASMB $19.93
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- ASMB 63.34
- LPTX 48.47
- Support Level
- ASMB $18.13
- LPTX $0.28
- Resistance Level
- ASMB $19.11
- LPTX $0.36
- Average True Range (ATR)
- ASMB 0.81
- LPTX 0.03
- MACD
- ASMB -0.06
- LPTX 0.01
- Stochastic Oscillator
- ASMB 77.83
- LPTX 69.80
About ASMB Assembly Biosciences Inc.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patients with colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein.